Has Anand Ganesan, MD received payments from drug or device companies?

Yes. Drug and device makers reported $10,336 in general payments to Anand Ganesan, MD across 6 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Anand Ganesan, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Anand Ganesan, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Anand Ganesan, MD

Dermatology · Orange, CANPI 1104895580

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $10,317 of the $10,336 with a category attached, or 99.8%. AbbVie accounts for 71.5% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $4,394 and has fallen 99.6% since, to $19 in 2025.

$10,336in general payments, 2019–2025

Across 6 payments — averaging $1722.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$7K
Avita Medical Americas, LLC$3K
Teva Pharmaceuticals USA, Inc.$19

$2,393,630in research payments, 2019–2025

Across 204 payments — averaging $11,733 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

AbbVie$1M
Incyte Corporation$766K
Avita Medical Americas, LLC$570K
Pfizer$13K

What the payments were for

Consulting fees$10,317100%
Food & beverage$190%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie(2 entities)	3	$7,394
Avita Medical Americas, LLC	2	$2,923
Teva Pharmaceuticals USA, Inc.	1	$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

RECELL$2,923
LATISSE$2,775

How this compares

$10,336 in reported general payments places this provider in the 80th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California →

Medicare billing

Part B allowed, 2024

$39,447

Medicare patients

127

Services billed

381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
RinvoqUpadacitinib	13	$81,633
OpzeluraRuxolitinib Phosphate	38	$73,237
Dupixent SyringeDupilumab	14	$56,731
Tacrolimus	11	$1,666
Clobetasol Propionate	18	$1,132
Tranexamic Acid	13	$865
MethotrexateMethotrexate Sodium	30	$512
Mycophenolate Mofetil	15	$505
Clobetasol EmollientClobetasol Propionate/Emoll	11	$295
Ciclopirox	13	$218
Spironolactone	14	$189
Dexamethasone	11	$184
Triamcinolone Acetonide	19	$159

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieRinvoq	$7,394	$81,63313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,875 dermatology providers in California.

Other dermatology in Orange

Paul YamauchiSanta Monica$2.9M
Jennifer SoungSanta Ana$2.8M
Robert GreenbergLivermore$2.6M
Neal BhatiaSan Diego$2.5M
April ArmstrongLos Angeles$2.3M
Jeffrey CrowleyBakersfield$2.1M
Jashin WuCorona$2M
Raja SivamaniSacramento$1.9M
Tien NguyenFountain Valley$1.2M
Tina BhutaniSan Francisco$1.1M

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →